Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...

Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...